Form 4: Vigil Neuroscience CEO Receives Stock Option Grant

Ivana Magovcevic-Liebisch, President and CEO of Vigil Neuroscience, Inc., was granted a stock option to purchase 463,000 shares of common stock on March 1, 2024.

Summary

• On March 1, 2024, Ivana Magovcevic-Liebisch, the President and CEO of Vigil Neuroscience, Inc., received a stock option grant.
• The grant allows her to purchase 463,000 shares of the company's common stock at an exercise price of $3.39 per share.
• The stock options vest in 48 equal monthly installments, beginning on April 1, 2024.
• The options expire on March 1, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.

Positives

• The stock option grant aligns the CEO's interests with those of the shareholders, incentivizing her to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant is likely determined by factors such as company size, market capitalization, and the executive's role and experience.
• Comparing the grant to similar companies like Denali Therapeutics or Biohaven Pharmaceuticals would provide a better understanding of its relative value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with their own.
• Employees may see it as a sign of the company's commitment to its leadership.

Key Dates